Publications by authors named "F Ruberg"
Cardiac amyloidosis represents a unique disease process characterized by amyloid fibril deposition within the myocardial extracellular space. Advances in multimodality cardiac imaging enable accurate diagnosis and facilitate prompt initiation of disease-modifying therapies. Furthermore, rapid advances in multimodality imaging have enriched understanding of the underlying pathogenesis, enhanced prognostication, and resulted in the development of imaging-based markers that reflect the amyloid burden, which is of increasing importance when assessing the response to treatment.
View Article and Find Full Text PDFArticle Synopsis
- - Transthyretin cardiac amyloidosis (ATTR-CA) is more commonly diagnosed in older men, but research indicates that women may be underrepresented in previous statistics regarding its prevalence.
- - The SCAN-MP study used nuclear imaging to assess ATTR-CA in older Black and Caribbean Hispanic individuals, revealing that this cohort had a higher percentage of women (31.3%) compared to a referral center (13.3%).
- - Women in the SCAN-MP cohort displayed a less severe form of the disease, indicated by higher heart function and lower heart mass, suggesting that targeted identification in women is essential to address existing sex disparities in ATTR-CA diagnoses.
Background: In light-chain (AL) amyloidosis, whether functional status and heart failure-related quality of life (HF-QOL) correlate with cardiomyopathy severity, improve with therapy, and are associated with major adverse cardiac events (MACE) beyond validated scores is not well-known.
Objectives: The authors aimed to: 1) correlate functional status and HF-QOL with cardiomyopathy severity; 2) analyze their longitudinal changes; and 3) assess their independent associations with MACE.
Methods: This study included 106 participants with AL amyloidosis, with 81% having AL cardiomyopathy.